Feb 6, 2026 08:00AM
Jan 12, 2026 02:00PM
Nov 24, 2025 08:00AM
Oct 17, 2025 10:00AM
Oct 16, 2025 03:53PM
Oct 16, 2025 03:51PM
Sep 17, 2025 08:00AM EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
May 28, 2025 07:00AM
May 22, 2025 05:37PM
Apr 28, 2025 02:13AM
Apr 24, 2025 03:32PM
Nov 12, 2024 01:18AM
Sep 12, 2024 08:00AM
Sep 10, 2024 08:00AM MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
May 23, 2024 05:00PM
May 22, 2024 01:35PM
Apr 16, 2024 08:00AM
Feb 29, 2024 08:00AM
Jan 22, 2024 05:00PM
Oct 16, 2023 02:00AM
Oct 16, 2023 02:00AM EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
Oct 10, 2023 02:15AM
May 25, 2023 05:05PM
Mar 27, 2023 08:00AM
Feb 23, 2023 10:30AM
Feb 13, 2023 05:00PM
Oct 26, 2022 02:00AM
Sep 7, 2022 06:05PM Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
Sep 7, 2022 06:05PM
Jun 3, 2022 08:00AM
May 26, 2022 12:00PM
Mar 31, 2022 09:00AM
Feb 24, 2022 08:00AM
Feb 18, 2022 01:00PM
Feb 18, 2022 08:00AM Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
Feb 17, 2022 03:41PM
Dec 17, 2021 07:00AM
Oct 13, 2021 07:00AM
Oct 4, 2021 03:00AM
Sep 12, 2021 06:05PM
May 19, 2021 05:00PM
Apr 23, 2021 09:25AM EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
Feb 25, 2021 08:00AM
Feb 3, 2021 01:43PM
Jan 25, 2021 02:00AM
Dec 11, 2020 08:00AM
Sep 18, 2020 03:00AM
Sep 13, 2020 06:05PM
Sep 3, 2020 08:00AM EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
Aug 25, 2020 09:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All